Ph3 Study of ABBV-383 in therapies in subjects with Mul Myeloma (3L+RRMM Montherapy Study)
Phase III Clinical Trial
A Phase 3 Multicenter Randomized Open-Label Study of Etentamig Compared with Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (M22-574)